Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




PET Impact Found Consistent Across Cancer Types and Imaging Indications

By HospiMedica International staff writers
Posted on 02 Dec 2008
New data provided by positron emission tomography (PET) imaging were found to affect how clinicians manage their cancer patients' care regardless of the cancer type and reason for ordering this imaging scan, according to results from a U.S. More...
PET registry.

The findings, from the [U.S.] National Oncologic PET Registry (NOPR; Philadelphia, PA, USA), was published online November 7, 2008, in the Journal of Nuclear Medicine (JNM). Earlier in 2008, the study authors reported in the Journal of Clinical Oncology (JCO) aggregate data contributed to the NOPR during year one of operation that demonstrated clinicians changed the intended care of more than one in three cancer patients as the result of PET scan findings.

After two years of operation, with nearly twice the data for analysis, the researchers found the impact of PET to be noticeably consistent for a wide range of cancers and indications. For this follow up NOPR study, researchers analyzed data for 40,863 PET studies performed at 1,368 facilities participating in the NOPR in the United States during the registry's first two years of operation. The impact of PET was assessed for 18 cancer types in patients with pathologically confirmed cancer and for indication for testing that included initial cancer staging (14,365 scans), restaging (14,584 scans), or detection of suspected cancer recurrence (11,914 scans).

"For the purposes of guiding clinical practice and shaping coverage policy, it is important to determine the relative effects of PET for different cancer types and indications for testing," said Bruce Hillner, M.D., lead author for the study, and professor and eminent scholar in the department of internal medicine at Virginia Commonwealth University. "These results strongly indicate the utility of PET for managing cancer patient care across a broad spectrum of cancer types and imaging indications."

The National Oncologic PET Registry (NOPR) is a collaboration of the American College of Radiology Imaging Network (ACRIN), the American College of Radiology (ACR; Restin, VA, USA), and the Academy of Molecular Imaging (AMI; Los Angeles, CA, USA), to ensure access to U.S. Medicare reimbursement for certain types of PET scans.

Related Links:
National Oncologic PET Registry
American College of Radiology
ACR Imaging Network
Academy of Molecular Imaging



Gold Member
Blood Gas Analyzer
i-Check200
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Rapid Sepsis Test
SeptiCyte RAPID
Glucose Meter
StatStrip®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.